Impact of treatment delay on survival of oral/oropharyngeal cancers: Results of a nationwide screening program.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33047420.
- Also identified by DOI 10.1002/hed.26504 and PMC identifier 7820997.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the impact of treatment delay on survival of oral/oropharyngeal cancer (OSCC). We followed 5743 OSCCs between 2004 and 2009 from a population-based screening program and ascertained death until the end of 2012. The hazard ratios (HRs) of mortality from OSCC were 1.46 (1.30-1.65) and 1.18 (1.04-1.33) in univariable and multivariable analyses, respectively, for treatment delay longer than 6 weeks compared with that shorter than 3 weeks. The corresponding figures were 1.12 (1.01-1.24) and 1.00 (0.91-1.11) for treatment delay between 3 and 6 weeks. Advancing age (1.01), higher stage (stage II: 1.84, stage III: 2.97, stage IV: 6.33), cancer in tongue (1.37), or hard palate (1.63) had higher HR of mortality (P < .05). However, treatment at medical center had a lower mortality (0.83, 0.75-0.91) than local/regional hospital. Treatment delay longer than 6 weeks for OSCCs detected via a population-based screening program had unfavorable survival.
Medical subject headings
- Mouth Neoplasms
- Oropharyngeal Neoplasms